U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07122401) titled 'Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism' on Aug. 01.
Brief Summary: MT1013 is a first-in-class dual-target agonist. This study is a multicenter, randomized, double-blind, double-dummy phase III clinical study being conducetd to evaluate the efficacy and safety of MT1013 compared with active control cinacalcet in secondary hyperparathyroidism patients on maintenance dialysis. Subjects will be 1:1 randomized to receive MT1013 or cinacalcet for 26 weeks. Evaluations of iPTH, Ca, P, BMD, and biomarkers will be done across the study period, to compare efficacy and safety of MT1013 to cinacalcet.
...